CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD8 和 CD4 CAR-T 细胞与 tisagenlecleucel 治疗中枢神经系统淋巴瘤的结局和毒性相关
英文原题：CD8 and CD4 CAR-T cells are associated with outcome and toxicity of tisagenlecleucel in central nervous system lymphoma.
查看英文原题
CD8 and CD4 CAR-T cells are associated with outcome and toxicity of tisagenlecleucel in central nervous system lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
这些数据首次在 CNSL 患者中证实了这些机制，并强调了 CAR-T 细胞表型监测对预测疗效和毒性的相关性。
研究思路结论见上方概要
方法
本研究回顾性纳入24例接受tisagenlecleucel治疗的初发和继发CNSL患者。采用流式细胞术分析输注产品、血液和脑脊液中的CAR-T 细胞。
结果
在此，我们表明CD8+ CAR-T 细胞的强劲扩增与早期反应和更好的长期生存相关。此外，CD4+ CAR-T 细胞似乎在细胞因子释放综合征的发展中起着关键作用。
展开英文摘要原文
METHODS
Twenty-four patients with primary and secondary CNSL treated with tisagenlecleucel were retrospectively included in this study. CAR-T cells were analysed in infusion products, blood ans cerebrospinal fluid using flow cytometry.
RESULTS
Here, we show that robust expansion of CD8 + CAR-T cells was associated with early response and better long-term survival. Additionally, CD4 + CAR-T cells appeared to play a pivotal role in the development of cytokine release syndrome.
CONCLUSIONS
These data represent the first evidence of these mechanisms in CNSL patients and emphasize the relevance of CAR-T cell phenotype monitoring to predict efficacy and toxicity.
论文信息
- 作者
- Samara JA、Baron M、Gazzano M、Parizot C、Kirupaharan M、Guihot A、Miyara M、Gorochov G
- 第一作者单位
- Département d'Immunologie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris 75013, France.France
- 通讯作者单位
- Département d'Immunologie, Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris 75013, France; Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Sorbonne Université, Paris 75013, France. Electronic address: delphine.sterlin@aphp.fr.France
- 期刊
- Cytotherapy2025 Aug
- 原文标识
- PubMed 40544366 · DOI 10.1016/j.jcyt.2025.05.005